An advertisement for Pennsaid (diclofenac sodium topical solution) 1.5% w/w. The advertisement is in blue and white colors and has a picture of a bottle of the product at the center with wholesaler and ordering information. The bottle is white with a white label and a white cap. On top of the image there is text that reads "Now available: introducing the next-generation topical NSAID that treats the signs and symptoms of OA of the knee(s); the only FDA approved topical NSAID with DMSO a proven penetrating agent." The bottom of the advertisement has the product's indication and important risk information. At the bottom corners there are two logos one for Covidien and the other for Mallinckrodt.
Description
Type 
Category
Source 1 of 18
-
Date
None
Collection
-
Date
2010
Collection
-
Date
2010
Collection
-
Date
None
Collection
-
Date
2010
Collection
-
Date
None
Collection
-
Date
2010
Collection
-
Date
2010
Collection
-
Date
2010
Collection
-
Date
2010
Collection
-
Date
None
Collection
-
Date
None
Collection
-
Date
2010
Collection
-
Date
2010
Collection
-
Date
2010
Collection
-
Date
2010
Collection
-
Date
None
Collection
-
Date
2010
Collection
We encourage you to view the image in the context of its source document(s) and cite the source(s) when using these images. However, to cite just this image alone, click the “Cite This Image” button and then paste the copied text.
![A screenshot from the Exalgo website. It appears to show case studies for how to convert different example patients to Exalgo step-by-step. The website is of example patient Dennis and the "Dose Conversion" step is selected. The website has a blue and white color scheme with a blue header and black footer.<br /><br />The main text of the page reads "Exalgo could give Dennis the pain relief he wants - with a once-daily dose. Double-blind placebo-controlled withdrawal study of opioid-tolerant patients with low back pain (447 enrolled 268 randomized; 66[49%] EXALGO patients and 44 [31%) placebo patients completed the study". Below that there is additional section titled "Double-blind treatment phase" which provides more information about the study and shows a bar graph comparing a reduction in pain intensity scores for Exalgo patients as compared with a placebo. <br /><br />The bottom of the page also has important risk information. In the lower right corner there is an image of a person walking a dog on a leash with a tree in the background. The footer has the Exalgo logo and a navigation menu.](https://oida-resources-images.azureedge.net/public/full/e3632038-48ef-4cfd-bf64-2e725bffad73.png)
